OC-007 A Multicenter, Double-Blind, Placebo (PBO)-Controlled Ph3 Study of Ustekinumab (UST), AHuman MAB to IL-12/23P40, IN PTS with Moderately-Severely Active Crohn’s Disease (CD) Who are Naïve or not Refractory to anti-TNFΑ: UNITI-2
B. Feagan, WJ Sandborn(Mayo Clinic in Arizona), Ursula Seidler(Medizinische Hochschule Hannover), Zsolt Tulassay(Semmelweis University), Yinghua Lang, Stephan R. Targan(Cedars-Sinai Medical Center), JR Friedman(Janssen (Switzerland)), L-L Gao(Janssen (United States)), J F Colombel(European CanCer Organisation), Subrata Ghosh, P. Rutgeerts, S. B. Hanauer(University of Chicago), W de Villiers(University of Cape Town), Christopher Gasink(Janssen (United States)), Jewel Johanns(Johnson & Johnson (United States)), Bruce E. Sands(Icahn School of Medicine at Mount Sinai)
Cited by 6
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
A Genome-Wide Association Study Identifies <i>IL23R</i> as an Inflammatory Bowel Disease Gene
|Science|2006|3k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k